Buparlisib and pictilisib belong to pan‐PI3K kinase inhibitors, which have been tested as a single agent or combination regimes in many tumor types, such as breast cancer, squamous cell carcinoma of the head and neck, glioblastoma, and lymphoma.348, 349, 350. Here, PIK3CB is linked to breast carcinoma.